CompuGroup Medical (COP) AI Stock Analysis

34 Followers

CompuGroup Medical

(Hamburg:COP)

Select Model

Rating:60Neutral

Price Target:EUR 28.00▼(-0.53% Downside)

Action:reiterated

Date:10/22/25

CompuGroup Medical's overall stock score is driven by stable financial performance and operational efficiency. However, high valuation metrics and technical indicators suggest caution. The lack of earnings call data and corporate events limits additional insights.

Positive Factors

Recurring SaaS and diversified revenue streamsA mixed model of one‑time license sales plus subscription and cloud SaaS creates recurring revenue and higher customer lifetime value. This durability improves predictability, supports retention and upsell, and underpins multi‑year cash flow visibility for reinvestment and debt servicing.

Negative Factors

Moderate leverage and reliance on debt financingA moderate debt load reduces financial flexibility and raises sensitivity to interest costs and refinancing cycles. Over a multi‑month horizon this can constrain strategic moves, limit opportunistic M&A, and force prioritization of cash to debt service rather than growth or shareholder distributions.

CompuGroup Medical (COP) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 803.80M
Dividend Yield: 1.76%
Average Volume (3M): 1,996
Price to Earnings (P/E): 43.4
Beta (1Y): 0.25
Revenue Growth: ―
EPS Growth: ―
Country: Germany
Employees: 8,299
Sector: General
Sector Strength: 55
Industry: Medical - Healthcare Information Services

CompuGroup Medical Business Overview & Revenue Model

Company Description

CompuGroup Medical SE & Co. KGaA develops and sells software and information technology solutions for the healthcare sector worldwide. It operates in four segments: Ambulatory Information Systems (AIS), Pharmacy Information Systems (PCS), Hospital In...

How the Company Makes Money

CompuGroup Medical generates revenue through multiple streams, primarily by selling software licenses and providing subscription-based services to healthcare providers. Their core revenue model includes one-time fees for software licenses, ongoing ma...

CompuGroup Medical Financial Statement Overview

Summary

CompuGroup Medical demonstrates steady revenue growth and operational efficiency, with solid EBIT and EBITDA margins. However, challenges in net profitability and leverage management remain.

Income Statement

70Positive

Balance Sheet

65Positive

Cash Flow

75Positive

Financial statement breakdown
Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.16B	1.15B	1.19B	1.13B	1.03B	837.26M
Gross Profit	821.16M	965.14M	1.01B	958.16M	285.89M	712.95M
EBITDA	197.37M	206.90M	215.84M	231.36M	216.63M	192.49M
Net Income	27.00M	34.60M	45.92M	73.41M	68.97M	73.19M
Balance Sheet
Total Assets	2.02B	1.97B	1.90B	1.94B	1.79B	1.57B
Cash, Cash Equivalents and Short-Term Investments	128.64M	107.61M	64.54M	90.96M	107.63M	75.61M
Total Debt	826.65M	879.99M	766.94M	786.47M	741.31M	554.54M
Total Liabilities	1.37B	1.32B	1.23B	1.27B	1.18B	926.84M
Stockholders Equity	651.09M	647.91M	667.68M	672.42M	612.07M	638.67M
Cash Flow
Free Cash Flow	84.57M	65.66M	104.11M	63.99M	87.78M	94.20M
Operating Cash Flow	143.96M	128.88M	179.53M	145.03M	165.27M	149.93M
Investing Cash Flow	-108.83M	-105.28M	-124.33M	-145.41M	-163.98M	-457.12M
Financing Cash Flow	-35.70M	18.81M	-80.69M	-16.36M	30.15M	338.07M

CompuGroup Medical Technical Analysis

Technical Analysis SentimentNegative

Last Price28.15

Price Trends

50DMA28.32Negative

100DMA27.89Positive

200DMA27.34Positive

Market Momentum

MACD-0.05Positive

RSI43.80Neutral

STOCH41.33Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:COP, the sentiment is Negative. The current price of 28.15 is below the 20-day moving average (MA) of 28.90, below the 50-day MA of 28.32, and above the 200-day MA of 27.34, indicating a neutral trend. The MACD of -0.05 indicates Positive momentum. The RSI at 43.80 is Neutral, neither overbought nor oversold. The STOCH value of 41.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DE:COP.

CompuGroup Medical Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

DE:COP against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
DE:AFX	73Outperform	EUR 3.13B	21.43	5.52%	1.54%	-0.06%	-38.81%
DE:AJ91	72Outperform	EUR 53.28M	11.41	11.67%	9.52%	1.35%	-20.52%
DE:BC8	60Neutral	EUR 4.21B	17.29	12.00%	2.07%	7.74%	14.82%
DE:COP	60Neutral	EUR 1.48B	43.42	4.19%	1.76%	―	―
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
DE:M3V	55Neutral	EUR 36.40M	26.18	7.77%	4.77%	-6.92%	-67.82%
DE:ADN1	45Neutral	EUR 469.38M	25.95	9.65%	1.06%	12.73%	51.34%

* General Sector Average

Performance Comparison

DE:COP and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:COP	CompuGroup Medical	28.15	4.57	19.40%
DE:ADN1	adesso AG	73.70	-16.32	-18.13%
DE:BC8	Bechtle Aktiengesellschaft	33.88	0.17	0.50%
DE:AFX	Carl Zeiss Meditec	35.78	-5.06	-12.39%
DE:M3V	MeVis Medical Solutions	19.90	-4.19	-17.40%
DE:AJ91	DocCheck AG	10.50	-0.80	-7.10%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 22, 2025

CompuGroup Medical AI Stock Analysis